Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- William Wegener, MD, PhD
Gilead Sciences
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
64 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Krankenhaus Der Elisabethinen Linz
Linz, Austria
- Medical University Vienna
Vienna, Austria
- University Hospital Leuven
Leuven, Belgium
- Cancer Care Manitoba
Winnepeg, Manitoba, Canada
- Centre Hospitalier Université de Sherbrooke
Sherbrooke, Quebec, Canada
- Institut Bergonie
Bordeaux, Cedex, France
- Ico René Gauducheau
Nantes, Cedex 1, France
- Institut Paoli-Calmettes
Marseille, Cedex 9, France
- Centre Léon Bérard Cancerologie Medicale
Lyon, France
- Institut Paoli-Calmettes
Marseille, France
- Crlc Val D'Aurelle
Montpellier, France
- Hopital Cochin
Paris, France
- Soroka Medical Center
Beersheba, Israel
- Rambam Medical Center
Haifa, Israel
- Centrum Onkologii Instytut Im. M. Sklodowskiej-Curie - Warszawa
Warsaw, Poland
- Hospital Sant Joan de Reu
Reus, Tarragona, Spain
- Hospital Vall D'Hebrón
Barcelona, Spain
- Centro Integral Oncologico Clara Campal
Madrid, Spain
- Hospital Universitario Gregorio Marañón
Madrid, Spain
- Hospital Universitario la Paz
Madrid, Spain
- Hospital Universitario Ramon Y Cajal
Madrid, Spain
- Hospital Miguel Servet
Zaragoza, Spain
- Banner Md Anderson
Gilbert, Arizona, United States
- City of Hope National Medical Center
Duarte, California, United States
- Pacific Shores Medical Group
Long Beach, California, United States
- Cedars-Sinai Medical Center
Los Angeles, California, United States
- Whittingham Cancer Center
Norwalk, Connecticut, United States
- Michael and Dianne Bienes Comprehensive Cancer Center - Holy Cross Hospital
Fort Lauderdale, Florida, United States
- Baptist Cancer Institute
Jacksonville, Florida, United States
- Cancer Specialists of North Florida
Jacksonville, Florida, United States
- Mountain States Tumor Institute at St. Luke'S Regional Medical Center
Boise, Idaho, United States
- Illinois Cancer Specialists
Arlington Heights, Illinois, United States
- Indiana University Health Goshen Center for Cancer Care
Goshen, Indiana, United States
- Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
- Ashland-Bellefonte Cancer Center
Ashland, Kentucky, United States
- University of Maryland Medical Center
Baltimore, Maryland, United States
- Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
- Henry Ford Health System
Detroit, Michigan, United States
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
- University of Mississippi Medical Center
Jackson, Mississippi, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2013
- Primary completion
- 30 Nov 2016
- Completion
- 30 Nov 2016
- Last update posted
- 16 Aug 2021
- Registered enrollment
- 334
- Registry id
- NCT01956812
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.